# PulseSight Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pulsesight-therapeutics

- Industry: Biotechnology
- Headquarters: France
- Website: https://pulsesight.com/
- Latest round: Series A (Feb 13, 2025)
- Investors on record: 3

## About

Based in France, PulseSight Therapeutics specialises in non-viral, minimally invasive gene therapies for severe retinal diseases, primarily age-related macular degeneration (AMD) and its various forms. In February 2024, PulseSight Therapeutics raised seed funding co-led by investors +ND Capital, BB Pureos Bioventures, and Korea Investment Partners. As of February 2024, the company is led by CEO Judith Greciet.

The company's proprietary electro-transfection delivery device facilitates the administration of disease-modifying genes directly to the retina. PulseSight's product pipeline includes PST-809 for wet AMD and PST-611 for dry AMD/geographic atrophy, both at advanced stages of preclinical IND-enabling studies.


The company plans to use the February 2024 funding to expand operations and its R&D sector.

## Funding rounds

- Series A, Feb 13, 2025 — Pureos Bioventures
- Seed, Feb 28, 2024 — +ND Capital, Korea Investment Partners, Pureos Bioventures

## Investors

- +ND Capital (https://capitalatlas.ai/funds/nd-capital) — Seed
- Korea Investment Partners (https://capitalatlas.ai/funds/korea-investment-partners) — Seed
- Pureos Bioventures (https://capitalatlas.ai/funds/pureos-bioventures) — Seed, Series A